Ga-68-DOTATOC -PET in the management of pituitary tumours (PA) and Thyroid associated ophtalmopathy (TAO) - Ga-PET in PA and TAO

Department of Endocrinology, Sahlgrenska University Hospital0 个研究点开始时间: 2014年8月22日最近更新: 2014年11月17日

适应症

试验速览

暂无简介。

•Adult man or woman (over 18 years)
•Naïve, unoperated pituitary tumour with GH or ACTH or TSH production or NFPA without treatment with somatostatin analogues or dopamine agonists OR
•TAO with clinical activity score (CAS) of = 4 (less than 3 months) and Euthyroid for at least 6 weeks
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Patient who may not attend to the protocol according to the investigators opinion.
•Pregnancy or lactating
•Isolated prolactin producing tumours
•Overproduction of FSH or LH
•Carcinoids ie ectopic CRF production
•Known or suspected allergy to the trial product or related products.
•Dysthyroid optic neuropathy (DON)
•Ulcerative Keratitis
•Previous treatment with steroids for TAO (do not include prophylaxis for TAO in connection with radio iodine treatment)

发起方

Department of Endocrinology, Sahlgrenska University Hospital